Effect of Vitamin D Supplements On Hemoglobin Concentration in Patients with Iron Deficiency Anemia and Concurrent Vitamin D Deficiency:A Randomized Single Blind Placebo Controlled Trial

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 5173-5173
Author(s):  
Pankaj Malhotra ◽  
Basavaraj GS ◽  
Naresh Sachdeva ◽  
Jasmina Ahluwalia ◽  
Sanjay Bhadada

Abstract Abstract 5173 Background: The effect of vitamin D replacement on hemoglobin concentration in subjects with concurrent iron deficiency anemia and vitamin D deficiency is not known. Methods: In a single blinded randomized placebo controlled study, thirty subjects with iron deficiency anemia (serum ferritin < 15 ug/dl) were randomized to intervention arm (vitamin D 6 lakh IU IM once) or placebo. In all subjects, iron deficiency was corrected with parental iron. All the causes other than iron deficiency were excluded with appropriate investigation. The primary end point was rise in hemoglobin concentration. Results: Baseline age, BMI, hemogram, levels of serum ferritin, 25(OH)D and PTH were similar in both the arms. Twelve weeks after vitamin D replacement, there was significant increase in 25 (OH) D levels and decrease in PTH levels in subjects with intervention arm compared to placebo arm (p<0. 01). The increment in serum ferritin in both the group was similar. There was no further increase in hemoglobin concentration in intervention arm compared to placebo arm. Conclusion: Vitamin D replacement in subjects with iron deficiency anemia after iron correction does not improve hemoglobin concentration further. Disclosures: No relevant conflicts of interest to declare.

2014 ◽  
Vol 133 (1) ◽  
pp. 31-35 ◽  
Author(s):  
Basavraj Sooragonda ◽  
Sanjay Kumar Bhadada ◽  
Viral N. Shah ◽  
Pankaj Malhotra ◽  
Jasmina Ahluwalia ◽  
...  

Background: The effect of vitamin D replacement on hemoglobin (Hb) concentration in subjects with concurrent deficiencies of vitamin D and iron is not known. Methods: We report on an investigator-initiated, randomized, single-blinded, placebo-controlled, 12-week interventional trial. Thirty subjects with iron-deficiency anemia (serum ferritin <15 µg/l) were randomized to an intervention arm (cholecalciferol, i.e. vitamin D3, 0.6 million units i.m. once) or placebo. In all subjects, iron deficiency was corrected with parental iron. Other causes of anemia were excluded with appropriate investigation. The primary end point was a rise in Hb concentration. Results: Baseline parameters of age, BMI, hemogram values and levels of serum ferritin, 25-hydroxyvitamin D [25(OH)D] and parathyroid hormone (PTH) were similar in the 2 arms. Twelve weeks after vitamin D replacement, there was a significant increase in 25 (OH)D levels (57.7 ± 20.5 vs. 14.1 ± 6.2 ng/ml, p < 0.0001) and a decrease in PTH levels (32.4 ± 16.4 vs. 52.9 ± 18.4 pg/ml, p = 0.003) in subjects in the intervention arm when compared to the placebo arm. However, the increments in serum ferritin and Hb concentration in the intervention and placebo arm did not differ. Conclusion: Vitamin D replacement in subjects with iron-deficiency anemia after iron correction does not improve Hb concentration further.


Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 3210-3210
Author(s):  
Arun S. Shet ◽  
Sneha Pinto ◽  
Gopa Mitra ◽  
Pooja Subramaniam ◽  
Amit Mandal

Abstract Abstract 3210 Introduction: Iron deficiency anemia (IDA) is a major health problem worldwide. Although a clinical diagnosis is relatively simple, specific laboratory markers of IDA are lacking especially in the setting of inflammation. Ferritin, the current standard to define IDA is an acute phase protein that is non-specifically elevated during inflammation. Serum transferrin receptor level measurements although available are not yet standardized as a clinical tool. Serum hepcidin is a recently developed novel marker that is currently neither available nor standardized sufficiently. Furthermore, such assays require instrumentation, technical sophistication, and are expensive. Objectives: We sought to identify novel markers of IDA using mass spectrometry based proteomics. Identifying such markers could yield targets that once validated could serve cost effective point of care assays to detect iron deficiency anemia. Since there is evidence for oxidative damage mediated by reactive oxygen species in IDA, as a first step, we characterized and quantified posttranslational oxidative modifications of hemoglobin and tested their utility as biomarkers. Patients and Methods: We prospectively enrolled patients with IDA (defined as ferritin <12ng/ml in the presence of normal CRP and/or a bone marrow aspirate with “0” iron stores) and healthy controls (n = 23 and 15 respectively). Patients with diabetes, cardiovascular disease, renal disease, cerebrovascular disease and liver disease were excluded as these are conditions associated with preexisting oxidant stress. Erythrocytes from the blood of IDA patients and controls were isolated by centrifugation, washed in 0.9% saline, and lysed in distilled water to yield intracellular hemoglobin. Hemoglobin was then either studied further as an intact molecule or after digestion with trypsin. We used matrix assisted laser desorption ionization (MALDI - TOF) mass spectrometry to identify oxidative modifications of tryptic digested hemoglobin. We used electro spray ionization (ESI) mass spectrometry to identify and semiquantitate oxidative hemoglobin modifications by methods previously established and published by others and ourselves. Results: Using a combination of mass spectrometric methods, we identified 4 oxidative modifications of hemoglobin in patients with IDA and healthy controls (Table 1). Interestingly, a non enzymatic posttranslational modification of hemoglobin, glutathionyl hemoglobin, was found to be significantly increased in IDA patients compared with healthy controls (Glutathionyl hemoglobin % of beta chain; mean ± SD 0.169 ± 0.096 vs 0.077 ± 0.037; p = 0.001). Markers of oxidative stress (reduced RBC glutathione) were lower in IDA compared to healthy controls but the difference was not significant (mean ± SD 0.92 ± 0.53 vs 1.08 ± 0.52 mmol/L; p = 0.54). Glutathionyl hemoglobin levels correlated inversely with serum ferritin (Spearman rho -0.485; p < 0.05). Conclusions: Using two distinct proteomic methods, we identified oxidative posttranslational modifications of hemoglobin in IDA and healthy controls. Glutathionyl hemoglobin, an established marker of oxidative stress was elevated in patients with IDA and correlated inversely with serum ferritin. Overall, these findings suggest that glutathionyl hemoglobin has potential as a biomarker of IDA. Disclosures: No relevant conflicts of interest to declare.


Anemia ◽  
2015 ◽  
Vol 2015 ◽  
pp. 1-6 ◽  
Author(s):  
Betelihem Terefe ◽  
Asaye Birhanu ◽  
Paulos Nigussie ◽  
Aster Tsegaye

Iron deficiency anemia among pregnant women is a widespread problem in developing countries including Ethiopia, though its influence on neonatal iron status was inconsistently reported in literature. This cross-sectional study was conducted to compare hematologic profiles and iron status of newborns from mothers with different anemia status and determine correlation between maternal and neonatal hematologic profiles and iron status in Ethiopian context. We included 89 mothers and their respective newborns and performed complete blood count and assessed serum ferritin and C-reactive protein levels from blood samples collected from study participants. Maternal median hemoglobin and serum ferritin levels were 12.2 g/dL and 47.0 ng/mL, respectively. The median hemoglobin and serum ferritin levels for the newborns were 16.2 g/dL and 187.6 ng/mL, respectively. The mothers were classified into two groups based on hemoglobin and serum ferritin levels as iron deficient anemic (IDA) and nonanemic (NA) and newborns of IDA mothers had significantly lower levels of serum ferritin (P=0.017) and hemoglobin concentration (P=0.024). Besides, newborns’ ferritin and hemoglobin levels showed significant correlation with maternal hemoglobin (P=0.018;P=0.039) and ferritin (P=0.000;P=0.008) levels. We concluded that maternal IDA may have an effect on the iron stores of newborns.


Biomedicine ◽  
2020 ◽  
Vol 39 (2) ◽  
pp. 268-273
Author(s):  
N. L Sharanya Raj ◽  
U Ajay Sharma ◽  
M. L Revathi Devi ◽  
S. M Purushothama ◽  
S. N Manjunath ◽  
...  

Introduction and Aim: Iron deficiency anemia is the commonest cause of anemia in developing country like India in all age groups. It is most easy to prevent as well as to treat. Its diagnosis and treatment are based on serum ferritin levels in developed countries which is not possible in India at primary healthcare setting. This study was undertaken to explore if red cell indices could replace serum ferritin in detecting iron deficiency. Materials and Methods: Study of association of red cell indices like Mean Corpuscular Volume (MCV), Mean Corpuscular hemoglobin (MCH), Mean Corpuscular hemoglobin Concentration (MCHC), Red cell Distribution Width (RDW) and Hemoglobin concentration (Hb%) with iron deficiency anemia and the correlation of these Red cell indices and Hb% with serum ferritin was done in 220 anemia patients of all age groups with Hb% <12g/dL. Results: Descriptive data showed skewed distribution of serum ferritin. Statistically significant reduction in all red cell indices values among iron deficiency anemia patients and statistically significant correlation of all red cell indices values except red cell distribution width with serum ferritin was found. Conclusion: Unlike developed countries we can use simple estimation of hemoglobin concentration along with red cell indices for diagnosing iron deficiency anemia in primary healthcare setting of India.  


1998 ◽  
Vol 8 (3) ◽  
pp. 223-229 ◽  
Author(s):  
Michael J. Ashenden ◽  
David T. Martin ◽  
Geoffrey P. Dobson ◽  
Colin Mackintosh ◽  
Allan G. Hahn

The aim of this study was to establish whether extremely low serum ferritin values in female athletes were associated with indications of iron deficiency anemia and whether serum ferritin values were influenced by the type of training or participants' body size. Hematological data collected during 6 years at the Australian Institute of Sport were reviewed to quantify changes in serum ferritin concentration associated with training and to establish whether decrements in serum ferritin were associated with any change in hemoglobin concentration, mean corpuscular volume, or mean corpuscular hemoglobin concentration. Mean serum ferritin concentrations of 7.5 μg ⋅ L−1 were not associated with any indication of iron-deficiency anemia. Serum ferritin declined by approximately 25% with the onset of rigorous daily training (p <.01) whether training was predominantly weight-bearing or non-weight-bearing. Rowers had significantly higher ferritin concentrations than basketball players of similar stature (p = .02). We conclude that considerable background information such as the stage of training, specific sport, and previous blood results should be sought when interpreting serum ferritin concentrations in female athletes.


Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 3353-3353
Author(s):  
Alix O'Meara ◽  
Laura Infanti ◽  
Jörg Sigle ◽  
Martin Stern ◽  
Andreas S. Buser

Abstract Abstract 3353 Iron store depletion is a common side effect of whole-blood donation. Iron loss may lead to iron deficiency symptoms such as fatigue, decreased physical and job performance then gradually result in iron deficiency anemia. As of 2004, routine serum ferritin testing was implemented at our Center. We analyzed the impact of this measure on our donor population with regard to hemoglobin level, anemia occurrence and donor deferral due to low hemoglobin. A total of 160'612 intended donations of 23'557 healthy blood donors at a single institution (Blutspendezentrum beider Basel, Basel, Switzerland) between 1996 and 2009 were analyzed. At each visit, complete blood counts were taken from fingerprick samples and donors were deferred if the capillary hemoglobin concentration proved <133 g/L (m) or <123 g/L (f). From 2004 on, serum ferritin was measured systematically. Upon detection of ferritin levels indicative of iron depletion or iron deficiency anemia, donors were contacted by a blood bank physician and received medical counseling. The further procedure of iron supplementation, donation interval extension or GP referral in the case of abnormal history remained at the physician and donor's discretion.Our donor population consisted of 10'893 males and 12'664 females, 8165 being women of childbearing age (age 18–45). Mean hemoglobin concentration of male donors rose from 151.7 g/L (before 2004) to 153.6 g/L after 2004 (difference 1.9 g/L, 95% CI 1.7 – 1.9 g/L). In women of all ages, the mean hemoglobin concentration increased from 135.7 to 138.3 g/L (difference 2.6 g/L, 95% CI 2.4 – 2.7 g/L) (Figure 1). The hemoglobin concentration of women of childbearing age was 134.2 g/L before 2004 and 137.0 g/L thereafter (difference 2.8 g/L, 95% CI 2.6 – 3.0 g/L). To rule out an alternative cause for the increase in hemoglobin, we assessed the evolution of hemoglobin levels in the periods of 1996–2003 and 2004–2009. In the former period, hemoglobin levels decreased at a mean rate of 0.22 g/L (95% CI -0.19 - -0.26 g/L) per year in male donors, whereas no significant change was seen in female donors (mean change 0.04 g/L, 95% CI -0.01 – 0.09 g/L). In the second period (2004 – 2009), mean hemoglobin levels increased in both male (mean increase per year 0.20 g/L, 95% CI 0.14 – 0.25 g/L) and female donors (mean increase per year 0.16 g/L, 95% CI 0.09 – 0.23 g/L). Before the introduction of routine ferritin measuring, 1.6% (95% CI 1.5 – 1.7%) of donors showed anemia according to WHO definitions (m: Hb<130; f: Hb<120). Anemia occurred in 1.1% of our donors after 2004 (95% CI 1.0 – 1.2%, difference before/after 2004 0.5%, 95% CI -0.6 – -0.3%). Frequency of anemia declined in both male donors (before 2004 0.7%, after 2004 0.5%) and in female donors (before 2004 3.6%, after 2004 2.2%). In the group of women of childbearing age, 4.9% (95% CI 4.6 – 5.3%) were anemic before and 3.1% (95% CI 2.7– 3.4%) after 2004 (difference before/after 2004 -1.8%, 95% CI -1.4 – -2.4%). In all visits to our center before 2004, 2.8% of donors (95% CI 2.7 – 2.9%) were not accepted for phlebotomy due to a hemoglobin count below the mandatory threshold. After 2004, the percentage of rejected donors due to a low hemoglobin count decreased to 1.9% (95% CI 1.8 – 2.0%, difference before/after 2004 -0.9%, 95% CI -0.7 – -1.0%). In particular in the group of women in childbearing age a clear reduction of the rejection rates was noted (before 2004: 7.6% CI 7.2 – 8.1%, thereafter: 4.8% CI 4.4 – 5.2%, difference before/after 2004 -2.8%, 95% CI -2.2 – -3.4%). In conclusion, the introduction of systematic serum ferritin measurements allowed an optimized management of donors with iron deficiency, with efficacious prevention of iron deficiency anemia. This resulted in an increase of mean hemoglobin levels in blood donors particularly in women of childbearing age, the population at highest risk for iron deficiency anemia. Both the incidence of pre-donation anemia and the frequency of donors rejected due to low hemoglobin decreased significantly. Disclosures: No relevant conflicts of interest to declare.


Author(s):  
Vidya A. Thobbi ◽  
Zeba Naz M. Bijapur

Background: Iron deficiency anemia is the most common form of anemia and nutritional disorder worldwide. Oral iron therapy and blood transfusion has many drawbacks like noncompliance and risk of transmittable infections and transfusion reaction. The modern alternative therapy is treatment with intravenous iron. Present study compares the efficacy, safety and tolerability between intravenous iron sucrose and oral iron in iron deficiency anemia during 20-36 weeks of pregnancy.Methods: It was a randomized controlled study between December 2017 to September 2019. 200 patients attending antenatal OPD in Al Ameen Medical College, with haemoglobin levels between 7-9.9 gm/dl and serum ferritin of <15 ng/ml were enrolled. In intravenous group, 200 mg iron sucrose in 100ml normal saline was infused alternate day till the required dose was met. The oral group received 200 mg of oral iron ascorbate along with folic acid 1.5 mg per day for 6 weeks.  Treatment efficacy was assessed by Hb and serum ferritin after 3 and 6 weeks.Results: Out of 200 patients, an increase in Hb was observed in both groups, rising from 9.7 g/dl to 10.3 g/dl and 10.9 g/dl after 3 weeks and 6 weeks respectively in oral group and from 8.6 g/dl to 9.8 g/dl and 10.8 g/dl after 3 weeks and 6 weeks respectively in intravenous group. Similar results were seen in ferritin levels. Rise in Hb and ferritin levels were greater in intravenous group than in oral group.Conclusions: Intravenous iron sucrose appears to be a better treatment option in comparison with oral iron, without serious side effects, better compliance and improved efficacy in correction of anaemia of pregnancy.


2010 ◽  
Vol 5 (1) ◽  
pp. 26
Author(s):  
Luh Seri Ani ◽  
Made Bakta ◽  
INT Suryadhi ◽  
IN Bagiada

<p class="MsoTitle" style="margin: 0cm 11.25pt .0001pt 14.2pt; text-align: justify; text-indent: 1cm;"><span style="font-size: 10pt;">Serum ferritin and hemoglobin concentration were used to iron deficiency anemia (IDA) tests over population. The prevalence of IDA prevalence in pregnant women </span><span style="font-size: 10pt;" lang="en-us" xml:lang="en-us">were</span><span style="font-size: 10pt;"> 18% over the world, 37</span><span style="font-size: 10pt;">.5% in Asia, and 46.5% in Bali. The iron supplementation that was administrated during pregnancy did not clinically proven to solve the problems. It was predicted that the IDA was existing before pregnant. So, the body iron store must be prepare before pregnancy period. This research aimed to know the serum ferritin and hemoglobin concentration in the new married women in Bali. The design of this research </span><span style="font-size: 10pt;" lang="en-us" xml:lang="en-us">was</span><span style="font-size: 10pt;"> descriptive cross sectional study and conducted at 276 new married women by multistage sampling method. Every participant was interviewed for characteristic data and taken blood sample to evaluate serum ferritin and hemoglobin. Serum ferritin and hemoglobin were examined by </span><span style="font-size: 10pt;">Immulite 2000 Ferritin and Sysmex SF-3000 and t</span><span style="font-size: 10pt;">he data were analyzed by descriptive analysis. The mean of serum ferritin and hemoglobin concentration are 29.41±20.36 µg/dl and 11.35±0.92 g/dl. The serum ferritin level proportions 20-29 µg/dl, less than 20 µg/dl, and ≥100 µg/dl are 145 (51.9%), 130 (47.1%), and 1(0.4%), eventually. The hemoglobin value &lt;12 g/dl was found in 36.2% population and amount 63.8% population with hemoglobin value ≥12 g/dl. According on iron status, the proportion of anemia </span><span style="font-size: 10pt;" lang="en-us" xml:lang="en-us">was</span><span style="font-size: 10pt;">23</span><span style="font-size: 10pt;">.6%, proportion of iron deficiency </span><span style="font-size: 10pt;" lang="en-us" xml:lang="en-us">was</span><span style="font-size: 10pt;">19</span><span style="font-size: 10pt;">.2% and proportion of IDA </span><span style="font-size: 10pt;" lang="en-us" xml:lang="en-us">was</span><span style="font-size: 10pt;">14</span><span style="font-size: 10pt;">.1%. Based on the result, ferritin in the new married women Bali </span><span style="font-size: 10pt;" lang="en-us" xml:lang="en-us">was</span><span style="font-size: 10pt;"> mostly low level but hemoglobin concentration </span><span style="font-size: 10pt;" lang="en-us" xml:lang="en-us">was</span><span style="font-size: 10pt;"> mostly normal. Although, they have problem in the proportion of iron deficiency, anemia and iron deficiency anemia, that </span><span style="font-size: 10pt;" lang="en-us" xml:lang="en-us">were</span><span style="font-size: 10pt;"> 19</span><span style="font-size: 10pt;">.2%, 23.6% and 14.1%, respectively.  </span></p><p class="MsoTitle" style="margin: 0cm 11.25pt .0001pt 14.2pt; text-align: justify; text-indent: 14.2pt;"> </p>


Author(s):  
Sajjad H. Naqvi ◽  
Syed Faizan-ul-Hassan Naqvi ◽  
Iftikhar H. Naqvi ◽  
Muhammad Farhan ◽  
Tanveer Abbas ◽  
...  

Author(s):  
Rashmi Pareek Ayatullah Hosne Asif ◽  
Nisha Kumari Ojha

Background: Anemia in adolescent girls possess greatest burden on their health as it leads to poor cognitive development, poor reproductive health and if not treated may lead to intrauterine growth retardation in their developing fetus. The prevalence of anemia among adolescent is 27% in developing country and 6% in developed country. The Government of India has launched National Anemia Control Programme, to prevent and control anaemia in children and adolescents. But the problem is still persisting because of many issues like - poor palatability, intolerance to the drug used, poor absorption of the drugs used, constipation, discoloration of stool, unpleasant odor and taste etc. result in poor compliance and therefore non adherence to the therapy which finally results in poor improvement. By looking at the magnitude of the problem, an Ayurveda drug Vajravatakmandura has been selected for the study and the present study was undertaken to evaluate the efficacy of the trial drug in iron deficiency anemia in adolescent girls. Material and methods: 100 subjects satisfying inclusion and exclusion criteria were selected and were randomly divided in two groups. In group A, the trial drug Vajravatakmaņdura was administered and in group B, IFA tablets were given for two month of duration with follow up at every fortnight. Result: Both the trial and control groups showed extremely significant result over subjective parameters. Trial drug Vajravatakmaņdura in group A was found more effective over the subjective parameters - weakness, palpitation, pallor and loss of appetite with % gain of 39.77%, 39.39%, 39.17%, 38.09% respectively. Statistical analysis between before and after treatment findings of objective parameters, extremely significant (P less than 0.0001) improvement was found in both groups in all parameters, except for RBC count in group A, which was significant. No adverse effects were reported during entire period of study by any of the patients in trial group treated with trial drug. Conclusion: The trial drug “Vajravatakmandura” is effective, safe and palatable for the management of iron deficiency anemia in adolescent girls.


Sign in / Sign up

Export Citation Format

Share Document